Literature DB >> 18847554

Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions.

Anna R Giuliano1, Guillermo Tortolero-Luna, Elena Ferrer, Ann N Burchell, Silvia de Sanjose, Susanne Kruger Kjaer, Nubia Muñoz, Mark Schiffman, F Xavier Bosch.   

Abstract

Human papillomavirus (HPV) infection is commonly found in the genital tract of men and women with or without any clinical lesion. The association of HPV DNA with several different ano-genital cancers other than cervical has been reported for the vulva, vagina, anus and penis. HPV DNA has also been identified in head and neck cancers in the oral cavity, the oropharynx and the larynx in both sexes. In men, 80-85% of anal cancers and close to 50% of penile cancers are associated with HPV infection. In women, HPV DNA is prevalent in 36-40% vulvar cancer cases and close to 90% of vaginal cancers. There is limited data available on the natural history and HPV-related diseases in the genital tract in men, although studies are ongoing. Efficacy of HPV vaccines in the prevention of HPV infection and disease among men also remains unknown. Among HPV DNA positive ano-genital cancer cases, HPV-16 is the most frequently found followed distantly by HPV-18. In benign HPV-related diseases such as genital warts or recurrent respiratory papillomatosis HPV-6 and 11, the two most frequent non-oncogenic types, are the predominant types detected. Oncogenic types are rarely detected. In this article we summarize and review studies describing the natural history of HPV infections among men and its impact on HPV related disease in women. We summarize the evidence linking HPV in the epidemiology and etiology of cancers of the vulva, vagina, anus and oropharynx and present recent estimates of the burden of and HPV type distribution in genital warts and in cases of HPV infection of the airways.

Entities:  

Mesh:

Year:  2008        PMID: 18847554      PMCID: PMC4366004          DOI: 10.1016/j.vaccine.2008.06.021

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  75 in total

1.  Laryngeal papillomas: histomorphometric evaluation of multiple and solitary lesions.

Authors:  H Lindeberg
Journal:  Clin Otolaryngol Allied Sci       Date:  1991-06

2.  Trends in the incidence of invasive and in situ vulvar carcinoma.

Authors:  Patricia L Judson; Elizabeth B Habermann; Nancy N Baxter; Sara B Durham; Beth A Virnig
Journal:  Obstet Gynecol       Date:  2006-05       Impact factor: 7.661

Review 3.  Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.

Authors:  Aimee R Kreimer; Gary M Clifford; Peter Boyle; Silvia Franceschi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-02       Impact factor: 4.254

4.  A population-based study of squamous cell vaginal cancer: HPV and cofactors.

Authors:  Janet R Daling; Margaret M Madeleine; Stephen M Schwartz; Katherine A Shera; Joseph J Carter; Barbara McKnight; Peggy L Porter; Denise A Galloway; James K McDougall; Hisham Tamimi
Journal:  Gynecol Oncol       Date:  2002-02       Impact factor: 5.482

5.  Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: results from a seroepidemiological case-control study.

Authors:  A Hildesheim; C L Han; L A Brinton; R J Kurman; J T Schiller
Journal:  Obstet Gynecol       Date:  1997-11       Impact factor: 7.661

6.  The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States.

Authors:  Anna R Giuliano; Eduardo Lazcano-Ponce; Luisa L Villa; Roberto Flores; Jorge Salmeron; Ji-Hyun Lee; Mary R Papenfuss; Martha Abrahamsen; Emily Jolles; Carrie M Nielson; Maria Luisa Baggio; Roberto Silva; Manuel Quiterio
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

Review 7.  Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers?

Authors:  Erich M Sturgis; Paul M Cinciripini
Journal:  Cancer       Date:  2007-10-01       Impact factor: 6.860

8.  Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men.

Authors:  Anna R Giuliano; Beibei Lu; Carrie M Nielson; Roberto Flores; Mary R Papenfuss; Ji-Hyun Lee; Martha Abrahamsen; Robin B Harris
Journal:  J Infect Dis       Date:  2008-09-15       Impact factor: 5.226

9.  Human papillomavirus (HPV) profiles of vulvar lesions: possible implications for the classification of vulvar squamous cell carcinoma precursors and for the efficacy of prophylactic HPV vaccination.

Authors:  Petr Skapa; Josef Zamecnik; Eva Hamsikova; Martina Salakova; Jana Smahelova; Kristyna Jandova; Helena Robova; Lukas Rob; Ruth Tachezy
Journal:  Am J Surg Pathol       Date:  2007-12       Impact factor: 6.394

10.  Effect of HIV infection on the natural history of anal human papillomavirus infection.

Authors:  C W Critchlow; S E Hawes; J M Kuypers; G M Goldbaum; K K Holmes; C M Surawicz; N B Kiviat
Journal:  AIDS       Date:  1998-07-09       Impact factor: 4.177

View more
  105 in total

1.  Functional characterization of CD4 and CD8 T cell responses among human papillomavirus infected patients with ano-genital warts.

Authors:  Manjula Singh; Deepshi Thakral; Narayan Rishi; Hemanta Kumar Kar; Dipendra Kumar Mitra
Journal:  Virusdisease       Date:  2017-06-13

2.  Novel microsphere-based method for detection and typing of 46 mucosal human papillomavirus types.

Authors:  Vanessa Zubach; Gerry Smart; Samuel Ratnam; Alberto Severini
Journal:  J Clin Microbiol       Date:  2011-11-23       Impact factor: 5.948

3.  Does framing human papillomavirus vaccine as preventing cancer in men increase vaccine acceptability?

Authors:  Annie-Laurie McRee; Paul L Reiter; Kim Chantala; Noel T Brewer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

4.  Determinants of prevalent human papillomavirus in recently formed heterosexual partnerships: a dyadic-level analysis.

Authors:  Ann N Burchell; Allita Rodrigues; Veronika Moravan; Pierre-Paul Tellier; James Hanley; François Coutlée; Eduardo L Franco
Journal:  J Infect Dis       Date:  2014-03-27       Impact factor: 5.226

5.  Correlation between physical status of human papilloma virus and cervical carcinogenesis.

Authors:  Kezhen Li; Xin Jin; Yong Fang; Changyu Wang; Mei Gong; Pingbo Chen; Jia Liu; Dongrui Deng; Jihui Ai
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-01-27

Review 6.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

7.  Cutaneous human papillomavirus types detected on the surface of male external genital lesions: a case series within the HPV Infection in Men Study.

Authors:  Christine M Pierce Campbell; Jane L Messina; Mark H Stoler; Drazen M Jukic; Massimo Tommasino; Tarik Gheit; Dana E Rollison; Laura Sichero; Bradley A Sirak; Donna J Ingles; Martha Abrahamsen; Beibei Lu; Luisa L Villa; Eduardo Lazcano-Ponce; Anna R Giuliano
Journal:  J Clin Virol       Date:  2013-10-16       Impact factor: 3.168

8.  Well-woman visit of mothers and human papillomavirus vaccine intent and uptake among their 9-17 year old children.

Authors:  Mahbubur Rahman; Lee B Elam; Michael I Balat; Abbey B Berenson
Journal:  Vaccine       Date:  2013-10-04       Impact factor: 3.641

9.  Views on HPV and HPV Vaccination: The Experience at a Federal Qualified Clinic in Puerto Rico.

Authors:  Vivian Colón-López; Lizbeth M Toro-Mejías; Alexandra Conde-Toro; Michelle J Serra-Rivera; Tania M Martínez; Verónica Rodríguez; Ana M Ríos; Luis Berdiel; Héctor Villanueva
Journal:  J Health Care Poor Underserved       Date:  2016

10.  Association of oncogenic and nononcogenic human papillomavirus with HIV incidence.

Authors:  Bertran Auvert; Pascale Lissouba; Ewalde Cutler; Kevin Zarca; Adrian Puren; Dirk Taljaard
Journal:  J Acquir Immune Defic Syndr       Date:  2010-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.